Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics[3] for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.[4] In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.[5]
^"Alnylam Pharmaceuticals Inc. Annual Income Statement". MarketWatch. 12 August 2023.
^"Alnylam Pharmaceuticals: Number of Employees 2006-2021". www.macrotrends.net.
^"Alnylam Pharmaceuticals Inc (ALNY) Quote - XNAS | Morningstar. Alnylam Pharmaceuticals Inc's Company Profile. Business Description". www.morningstar.com. Retrieved 15 May 2022.
^"ALNY | Alnylam Pharmaceuticals Inc. Company Profile & Executives - WSJ". www.wsj.com. Retrieved 15 May 2022.
^"Most Innovative Growth Companies #100 Alnylam Pharmaceuticals". Forbes. May 2016. Retrieved September 22, 2016.
and 27 Related for: Alnylam Pharmaceuticals information
AlnylamPharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference...
development of RNAi therapy for humans. AlnylamPharmaceuticals, Sirna Therapeutics and Dicerna Pharmaceuticals are few of the companies still working...
licensed non-exclusively the RNAi technology platform developed by AlnylamPharmaceuticals, creating a potentially long-term partnership between the companies...
of Inex Pharmaceuticals in 2007. Tekmira, as the company was formerly called, was formed as a wholly owned subsidiary of Inex Pharmaceuticals in 2005...
in 2018 with the siRNA drug patisiran, developed by AlnylamPharmaceuticals. Dicerna Pharmaceuticals, Persomics, Sanofi and Sirna Therapeutics also worked...
biotech start-ups. She also chairs the Board of Directors for AlnylamPharmaceuticals (NASDAQ: ALNY) and ByHeart, and represents Polaris as a director...
Transthyretin-Mediated Amyloidosis" (PDF). AlnylamPharmaceuticals. Archived (PDF) from the original on 9 October 2021. "AlnylamPharmaceuticals Reports Fourth Quarter and...
executive. She is chief operating officer of AlnylamPharmaceuticals, and from 1 January 2022 Alnylam's CEO. She is one of a small number of Black women...
confidence by the market in antisense technology. In 2007, Isis and AlnylamPharmaceuticals, which focuses on RNA interference, formed a 50/50 joint venture...
IL-2 receptor agonist program. In July 2023, Roche partnered with AlnylamPharmaceuticals in a deal worth $2.8 billion for the development of a hypertension...
of AlnylamPharmaceuticals; advisor and investor at Longwood and Polaris Venture Funds; a member of the Boards of Directors at Syros Pharmaceuticals and...
Julie Meyer, Author and Businesswoman Yvonne Greenstreet, CEO of AlnylamPharmaceuticals Philippe Harache, Former Deputy CEO, Eurocopter Franz Humer, Chairman...
developed by Ionis Pharmaceuticals and licensed to Akcea Therapeutics. Patisiran (sold under Onpattro) was developed by AlnylamPharmaceuticals, and also approved...
priority review voucher. The FDA granted the approval of Oxlumo to AlnylamPharmaceuticals, Inc. Lumasiran is available under the UK Early Access to Medicines...
for Health Security. Hamburg joined the board of directors for AlnylamPharmaceuticals in 2018. In 2020, Hamburg participated in the strategic framework...
Rastetter has been described as an "omnipotent biotech force" and by AlnylamPharmaceuticals CEO John Maraganore as an "industry legend" who has deep biotechnology...
property developed at the institute, such as AlnylamPharmaceuticals, Sanofi Genzyme, Ironwood Pharmaceuticals, Rubius Therapeutics, and Verastem. In 2019...
subsidiary of Novartis, which licensed the rights to inclisiran from AlnylamPharmaceuticals. The effectiveness of inclisiran was studied in three randomized...
regulatory phenomena. Bartel is a founder and a scientific advisor of AlnylamPharmaceuticals, a company started in 2002 to advance “RNAi (RNA interference)...
executive officer and a member of the board of directors at AlnylamPharmaceuticals. At Alnylam, he led the company’s pioneering efforts to advance RNA interference...
appointed the chairman of the board of AlnylamPharmaceuticals in December 2015. His chairmanship at Alnylam was coupled with a total compensation of...
and AlnylamPharmaceuticals, a US biotechnology company developing RNAi therapeutics, announced that Genyzme would invest $700 million in Alnylam. Under...
Financials Property & Casualty Insurance Ally Financial ALLY Financials AlnylamPharmaceuticals ALNY Health Care Alphabet (Class A) GOOGL Communication Services...
Global Information
US$1.83 billion (2023)
US$1.04 billion (2022)[1]